76 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.
Dana-Farber Cancer Institute
Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Dana-Farber Cancer Institute
Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
Dana-Farber Cancer Institute
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish.
Dana-Farber Cancer Institute
Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Dana-Farber Cancer Institute
Covalent Stapling of the Cereblon Sensor Loop Histidine Using Sulfur-Heterocycle Exchange.
Dana-Farber Cancer Institute
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.
Dana-Farber Cancer Institute
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.
Dana-Farber Cancer Institute
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.
Dana-Farber Cancer Institute
Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19.
Dana-Farber Cancer Institute
A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders.
Dana-Farber Cancer Institute
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.
Dana-Farber Cancer Institute
Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing.
Dana-Farber Cancer Institute
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.
Dana-Farber Cancer Institute
Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
Dana-Farber Cancer Institute
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.
Dana-Farber Cancer Institute
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.
Dana-Farber Cancer Institute
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Dana-Farber Cancer Institute
Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
Dana-Farber Cancer Institute
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
Dana-Farber Cancer Institute
Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8.
Dana-Farber Cancer Institute
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Dana-Farber Cancer Institute
Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.
Dana-Farber Cancer Institute
OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28
Carmot Therapeutics
NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Shanghai Hansoh Biomedical
Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof
280 Bio
FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
Enliven Therapeutics
Therapeutic agent for non-motor symptoms associated with Parkinson's disease
Sumitomo Pharma
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
Prelude Therapeutics
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine
Vtv Therapeutics
Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
Inflarx
Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof
Shanghai Institute of Material Medica, Chinese Academy of Sciences
N4-hydroxycytidine and derivatives and anti-viral uses related thereto
Emory University
Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
Valo Early Discovery
Piperidine derivatives as inhibitors of ubiquitin specific protease 7
Almac Discovery
6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
University of Pittsburgh
Composition for suppressing neuraminidase activity comprising geranylated flavonoid derived from Paulownia tomentosa as active ingredient
Industry-Academic Cooperation Foundation Gyeongsang National University
Substituted 7-azabicycles and their use as orexin receptor modulators
Janssen Pharmaceutica
Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
Hanmi Pharm.
Isatin based Schiff bases as inhibitors of a-glucosidase: Synthesis, characterization, in vitro evaluation and molecular docking studies.
Hazara University
(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
Sanofi
INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE.
California Institute of Technology
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
University of Arizona
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity.
F. Hoffmann-La Roche